Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.39 |
| ▸ | HTR3B | O95264 | 2/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.39 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fabesetron SCHEMBL1350066 | 1.00 | HTR3A (0.47) | HTR3ACYP3A4KCNH2CYP1A2HTR2B | |
| Fabesetron SCHEMBL30949355 | 1.00 | HTR3A (0.47) | HTR3ACYP3A4KCNH2CYP1A2HTR2B | |
| Fabesetron SCHEMBL2232218 | 0.99 | CASP6 (0.48) | HTR3ACYP3A4KCNH2CYP1A2HTR2B | |
| Fabesetron SCHEMBL1026223 | 0.99 | CASP6 (0.48) | HTR3ACYP3A4KCNH2CYP1A2HTR2B | |
| Fabesetron SCHEMBL8038329 | 0.98 | HTR3A (0.46) | HTR3ACYP3A4KCNH2CYP1A2HTR2B | |
| Fabesetron SCHEMBL9292924 | 0.92 | HTR3A (0.42) | HTR3ACYP3A4KCNH2CYP1A2HTR2B | |
| Fabesetron SCHEMBL9292920 | 0.92 | HTR3A (0.42) | HTR3ACYP3A4KCNH2CYP1A2HTR2B | |
| SCHEMBL7276284 | 0.89 | HTR3A (0.45) | HTR3ACYP3A4KCNH2CYP1A2HTR2B | |
| Hydrochloric Acid SCHEMBL7337938 | 0.88 | CASP6 (0.46) | HTR3ACYP3A4KCNH2CYP1A2HTR2B | |
| SCHEMBL7267456 | 0.88 | HTR3A (0.37) | HTR3ACYP3A4KCNH2CYP1A2HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0993829-B1 | TRANSDERMAL PREPARATION CONTAINING SEROTONIN RECEPTOR ANTAGONIST | HISAMITSU PHARMACEUTICAL CO (JP) | 2011-01-12 | — | — | EP | claimed |
| EP-1503764-B1 | 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE | SERODUS AS (NO) | 2010-01-06 | — | — | EP | claimed |
| EP-1503764-A1 | 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE | MEDINNOVA AS (NO) | 2005-02-09 | — | — | EP | claimed |
| WO-2003097065-A1 | 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE | MEDINNOVA AS (NO) | 2003-11-27 | — | — | WO | claimed |
| EP-0451538-B1 | Use of pyridoindole derivatives in the treatment of ischemic disorders | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-05-22 | — | — | EP | claimed |
| EP-0361317-B1 | Pyridoindole derivatives and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-04-05 | — | — | EP | claimed |
| US-5290785-A | Therapeutic agent for ischemic diseases | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-03-01 | — | — | US | claimed |
| US-5173493-A | For treatment or prevention of nausea or vomiting | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-12-22 | — | — | US | claimed |
| US-5141945-A | 5-Hydroxytryptamine antagonists, treatment or prevention of nausea and vomiting | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-08-25 | — | — | US | claimed |
| EP-0451538-A2 | Use of pyridoindole derivatives in the treatment of ischemic disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-16 | — | — | EP | claimed |
| EP-0361317-A2 | Pyridoindole derivatives and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-04-04 | — | — | EP | claimed |
| JP-2117675-A | — | — | None | — | — | JP | disclosed |
| JP-4270280-A | — | — | None | — | — | JP | disclosed |
| US-20090203792-A1 | METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING ALPHA2DELTA SUBUNIT CALCIUM CHANNEL MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| EP-1152761-B1 | USE OF 5-HT3 RECEPTOR ANTAGONISTS FOR TREATING MUSCULOESKELETAL DISEASES | NOVASEARCH AG (CH) | 2009-06-24 | — | — | EP | disclosed |
| JP-H04270280-A | THERAPEUTIC AGENT FOR ISCHEMIC DISEASE | FUJISAWA PHARMACEUT CO LTD | 1992-09-25 | — | — | JP | disclosed |
| US-5141945-A | 5-Hydroxytryptamine antagonists, treatment or prevention of nausea and vomiting | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-08-25 | — | — | US | disclosed |
| EP-0451538-A2 | Use of pyridoindole derivatives in the treatment of ischemic disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-16 | — | — | EP | disclosed |
| JP-H02117675-A | PYRIDOINDOL DERIVATIVE AND PRODUCTION THEREOF | FUJISAWA PHARMACEUT CO LTD | 1990-05-02 | — | — | JP | disclosed |
| EP-0361317-A2 | Pyridoindole derivatives and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203792-A1 | METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING ALPHA2DELTA SUBUNIT CALCIUM CHANNEL MODULATORS | GABRB2, CACNA1D, CACNA1B | HTR3A 468/4885CYP3A4 1997/4885KCNH2 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.